With the rapid development of precision cancer medicine, a better understanding of lung cancer-related gene mutations has allowed to detect mutations in genes such as EGFR, ALK, BRAF, HER2, met, ros1 and RET to stratify patients for better treatments, leading to increased survival time of lung cancer patients after targeted treatments [4–6]. Here, ERBB2 is linked to lung carcinoma.